Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 16/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13594816 | 1.00 | CHRM3 (0.47) | CHRM3HCRTR1HCRTR2 | |
| SCHEMBL14071820 | 0.88 | HCRTR1 (0.44) | CHRM3HCRTR1HCRTR2 | |
| SCHEMBL5962971 | 0.87 | HCRTR1 (0.38) | CHRM3HCRTR1HCRTR2 | |
| SCHEMBL13594856 | 0.84 | KMT2A (0.51) | CHRM3HCRTR1HCRTR2 | |
| SCHEMBL4413990 | 0.83 | ROCK2 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL13594838 | 0.83 | ROCK2 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL21352645 | 0.82 | HCRTR1 (0.41) | CHRM3HCRTR1HCRTR2 | |
| SCHEMBL21352644 | 0.82 | HCRTR1 (0.41) | CHRM3HCRTR1HCRTR2 | |
| SCHEMBL5962804 | 0.81 | HCRTR1 (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL5962846 | 0.80 | EPHX2 (0.44) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664049-B1 | SYNTHESIS OF PROTECTED PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2009-12-23 | — | — | EP | disclosed |
| US-7429658-B2 | Synthesis of protected pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-20060264622-A1 | Synthesis of protected pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264622-A1 | Synthesis of protected pyrrolobenzodiazepines | SBDS, DRD2, GRIN2D | CHRM3 2901/4885HCRTR1 1486/4885HCRTR2 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.